Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study)

Aim. To analyse factors hampering the achievement of compensation of carbohydrate metabolism in patients with type 2 diabetes mellitus treated for3 months with diabeton MB at a daily dose of 90-120 mg under real practical conditions. Materials and methods. This open study included 70 patients with type 2 diabetes mellitus given gliclazide MB-based hypoglycemic therapy(90-120 mg/day); their HbA 1c level was measured before and 3 months after the onset of therapy. Results. The treatment resulted in a significant decrease of the HbA 1c level especially pronounced in patients capable of following the rational therapeuticstrategy. At the closing visit, each patient was prescribed a pathogenetically sound regime of combined hypoglycemic therapy. Conclusion. Poor efficacy of hypoglycemic treatment in real clinical practice is attributable to frequent prescription of monotherapy, untimely onsetof insulin administration, its correction and intensification to meet changing requirements